Shangli Cai

Burning Rock Biotech - Department of Medicine

Guangzhou

China

SCHOLARLY PAPERS

8

DOWNLOADS

295

TOTAL CITATIONS

2

Scholarly Papers (8)

1.

Sintilimab Combined with Gemcitabine and Carboplatin for First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepithelioma-Like Carcinoma: A Multicenter, Single-Arm, Phase II Trial

Number of pages: 34 Posted: 04 Jan 2024
Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Government of the People's Republic of China - First People’s Hospital of Dongguan, Sun Yat-sen University (SYSU), Sun Yat-sen University (SYSU), Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - Department of Laboratory Medicine, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech and Guangzhou Medical University - State Key Laboratory of Respiratory Disease
Downloads 57 (743,032)

Abstract:

Loading...

Pulmonary lymphoepithelioma-like carcinoma, PD-1 inhibitor, sintilimab, Epstein-Barr virus, T-cell-inflamed gene-expression profile

2.

Identification SPTA1 Mutation as a Positive Predictive Biomarker for Immunotherapy by Associating with Cd8 + T Cell Infiltration in Lung Adenocarcinoma

Number of pages: 32 Posted: 02 Jul 2021
Chinese Academy of Medical Sciences - National Cancer Center, Peking University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Chinese Academy of Medical Sciences - National Cancer Center, Chinese Academy of Medical Sciences - National Cancer Center, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Medical Oncology
Downloads 57 (743,032)

Abstract:

Loading...

SPTA1, lung adenocarcinoma; CD8+ T cell infiltration; immunotherapy; predictive biomarker

3.

Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial

Number of pages: 37 Posted: 02 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Central South University - Thoracic Medicine Department II, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Jilin Cancer Hospital, China Medical University - Medical Oncology Department of Thoracic Cancer, Guangdong Pharmaceutical University - Department of Medical Oncology, Xuzhou Central Hospital, Jiangnan University - Affiliated Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Harbin Medical University, Wenzhou Medical University - Taizhou Hospital of Zhejiang Province, Linyi Cancer Hospital - Department of Medical Oncology, Zhejiang University - Second Affiliated Hospital, The First Affiliated Hospital of Guangxi Medical University, Shanghai Jiao Tong University (SJTU) - Department of Respiratory and Critical Care Medicine, Tangshan People’s Hospital, Shandong University - Shandong Cancer Hospital, Qingdao Central Hospital, ZhongDa Hospital of Southeast University, Huazhong University of Science and Technology - Department of Medical Oncology, Nanchang University - First Affiliated Hospital, Zhengzhou University - Henan Cancer Hospital, Government of the People's Republic of China - Second People's Hospital of Yibin, Peking University - Department of Thoracic Medical Oncology, Medical School of Nanjing University, Xiamen University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Zhengzhou University - Department of Oncology, Xinjiang Medical University - Affiliated Tumor Hospital, China Medical University - Department of Medical Oncology, Qingdao University - Affiliated Hospital, Nanchang University - Department of Medical Oncology, Shandong University - Qilu Hospital, Shanghai Pulmonary Hospital, Tianjin Medical University - Department of Medical Oncology, Nanjing University - Department of Respiratory Medicine, Anhui Provincial Cancer Hospital, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Guangzhou Medical University - Second Affiliated Hospital, Army Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Nantong Tumor Hospital - Department of Medical Oncology, First People's Hospital of Changzhou, Chongqing Medical University - Second Affiliated Hospital, Jilin University (JLU) - Cancer Center, Shanghai Jiao Tong University (SJTU) - Ruijin Hospital of Shanghai, Yangzhou University - Subei People's Hospital of Jiangsu Province, Anhui Provincial Cancer Hospital, Shanxi Provincial People's Hospital, Shanxi Provincial People's Hospital, Chinese Academy of Medical Sciences - Cancer Hospital, Nanjing Medical University - Nanjing First Hospital, Nanjing Medical University - Department of Oncology, ChangZhou Cancer Hospital, Nantong University - Department of Respiratory Medicine, First Hospital of Jiaxing, Fujian Provincial Cancer Hospital, Ground Force Medical University - Xinqiao Hospital, Xi’an Jiaotong University, Health Science Center, First Affiliated Hospital, TopAlliance Biosciences, TopAlliance Biosciences, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Shanghai Junshi Biosciences Co., LTD, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 45 (824,020)

Abstract:

Loading...

Non-small cell lung cancer, overall survival, immunotherapy, biomarker

4.

DNA Methylation of Biliary Tract Cancer Identifies Subtypes with Different Immune Characteristics and Clinical Outcomes

Number of pages: 31 Posted: 22 Jul 2021
Government of the People's Republic of China - Department of Biliary Tract Surgery I, Government of the People's Republic of China - Department of Laboratory Medicine, Burning Rock Biotech - Department of Medicine, Government of the People's Republic of China - Department of Pathology, Shanghai University of Traditional Chinese Medicine - Shanghai Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech - Department of Research and Developmentt, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech - Department of Bioinformatics, Burning Rock Biotech - Department of Research and Developmentt, Burning Rock Biotech - Department of Research and Developmentt, Burning Rock Biotech - Department of Medicine and Government of the People's Republic of China - Department of Biliary Tract Surgery I
Downloads 37 (888,638)
Citation 2

Abstract:

Loading...

5.

Efficacy and Safety Comparisons of Programmed Cell Death-1 vs Programmed Cell Death Ligand-1 Inhibitors in Patients with Cancer: A Systematic Review and Updated Meta-Analysis

Number of pages: 32 Posted: 11 Dec 2023
Tianjin Medical University - Tianjin Key Laboratory of Cancer Prevention and Therapy, Burning Rock Biotech, Burning Rock Biotech - Department of Medicine, Tianjin Medical University, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Tianjin Medical University, Tianjin Medical University, Tianjin Medical University, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech - Department of Medicine and Tianjin Medical University - State Key Laboratory of Experimental Hematology
Downloads 29 (963,483)

Abstract:

Loading...

PD-1, PD-L1, efficacy, safety, cancer

6.

T Proliferating Cells Derived Autophagy Signature Associated with Prognosis and Immunotherapy Resistance in a Pan-Cancer Analysis

Number of pages: 68 Posted: 17 Mar 2023
Jilin University (JLU) - Department of Hepatobiliary-Pancreatic Surgery, Burning Rock Biotech, Jilin University (JLU) - Genetic Diagnosis Center, Jilin University (JLU) - Cancer Center, Government of the People's Republic of China - Department of Hepatobiliary Surgery, Government of the People's Republic of China - Department of Hepatobiliary Surgery, Government of the People's Republic of China - Department of Hepatobiliary Surgery, Jilin University (JLU) - Department of Hepatobiliary-Pancreatic Surgery, Burning Rock Biotech, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech - Department of Medicine, Jilin University (JLU) - Department of Hepatobiliary-Pancreatic Surgery and Jilin University (JLU) - Department of Hepatobiliary-Pancreatic Surgery
Downloads 24 (1,016,812)

Abstract:

Loading...

autophagy, Pan-Cancer, immune checkpoint inhibitor, single-cell sequencing, immune resistance

7.

A Novel Prognostic and Immunotherapeutic Predictive Model Based on Cell-Originated Characterization of Tumor Microenvironment in Lung Adenocarcinoma

Number of pages: 34 Posted: 18 Nov 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Medical School of Nanjing University - Department of Oncology, Burning Rock Biotech, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech - Department of Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology
Downloads 23 (1,028,146)

Abstract:

Loading...

lung adenocarcinoma, tumor microenvironment, tumor immune cell score, immunotherapy, biomarker.

8.

Notch Pathway Defines an Aggressive and Immune-Suppressive Phenotype Associated with Checkpoint Inhibitor Resistance in Pan-Gastrointestinal Adenocarcinomas

Number of pages: 33 Posted: 20 Jul 2022
Sichuan Cancer Hospital - Department of Medical Oncology, Burning Rock Biotech, Fudan University - Endoscopy Center and Endoscopy Research Institute, Sichuan Cancer Hospital, University of Electronic Science and Technology of China (UESTC), University of Electronic Science and Technology of China (UESTC) - School of Medicine, Sichuan Cancer Hospital, Burning Rock Biotech, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Sciences (CAS) - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), University of Electronic Science and Technology of China (UESTC) - School of Medicine and Sichuan Cancer Hospital - Department of Medical Oncology
Downloads 23 (1,028,146)

Abstract:

Loading...

Notch pathway, gastrointestinal adenocarcinoma, prognostication, ICI resistance